New perspectives in the assessment of future remnant liver

Digestive Surgery

Volumn 31, Issue 4-5, 2014, Pages 255-268

  Cieslak, Kasia P ^a,b   Runge, Jurgen H ^a   Heger, Michal ^a   Stoker, Jaap ^a   Bennink, Roelof J ^a   Van Gulik, Thomas M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CT volumetry; Future remnant liver; Liver function; Liver scintigraphy; Preoperative assessment

Indexed keywords

ADVERSE EFFECTS; ANASTOMOSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEMOSTASIS; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; LIVER NEOPLASMS; LIVER RESECTION; MALE; MICROSURGERY; MINIMAL RESIDUAL DISEASE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SCINTISCANNING; SURVIVAL RATE; TREATMENT OUTCOME;

ANASTOMOSIS, SURGICAL; FEMALE; HEMOSTASIS, SURGICAL; HEPATECTOMY; HUMANS; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICROSURGERY; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84908288924     PISSN: 02534886     EISSN: 14219883     Source Type: Journal    
DOI: 10.1159/000364836     Document Type: Review

References (128)

1. van den Broek MA, Olde Damink SW, Dejong CH, Lang H, Malago M, Jalan R, Saner FH: Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 2008; 28: 767-780.
2. Cucchetti A, Cescon M, Ercolani G, Di Gioia P, Peri E, Pinna AD: Safety of hepatic resection in overweight and obese patients with cirrhosis. Br J Surg 2011; 98: 1147-1154.
3. Vetelainen R, van VA, Gouma DJ, van Gulik TM: Steatosis as a risk factor in liver surgery. Ann Surg 2007; 245: 20-30.
4. Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M: Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med 1979; 90: 185-187.
5. Shoup M, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, Tuorto S, Blumgart LH, Fong Y: Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003; 7: 325-330.
6. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T: Measurement of liver volume and hepatic functional reserve as a guide to decisionmaking in resectional surgery for hepatic tumors. Hepatology 1997; 26: 1176-1181.
7. Shirabe K, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T, Sugimachi K: Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999; 188: 304-309.
8. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN: Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94: 1386-1394.
9. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, Hicks M, Alsfasser G, Lauwers G, Hawkins IF, Caridi J: Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000; 127: 512-519.
10. Dinant S, de Graaf W, Verwer BJ, Bennink RJ, van Lienden KP, Gouma DJ, van Vliet AK, van Gulik TM: Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med 2007; 48: 685-692.
11. de Graaf W, van Lienden KP, van den Esschert JW, Bennink RJ, van Gulik TM: Increase in future remnant liver function after preoperative portal vein embolization. Br J Surg 2011; 98: 825-834.
12. Marsman HA, van der Pool AE, Verheij J, Padmos J, Ten Kate FJ, Dwarkasing RS, van Gulik TM, Ijzermans JN, Verhoef C: Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. J Surg Oncol 2011; 104: 10-16.
13. Clavien PA, Emond J, Vauthey JN, Belghiti J, Chari RS, Strasberg SM: Protection of the liver during hepatic surgery. J Gastrointest Surg 2004; 8: 313-327.
14. Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, Momose Y, Komiyama A, Makuuchi M: Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995; 21: 1317-1321.
15. Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, Lerut J, Materne R, Wang X, Encarnacion A, Herron D, Mathey C, Ferrari G, Charnsangavej C, Do KA, Denys A: Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002; 8: 233-240.
16. DeLand FH, North WA: Relationship between liver size and body size. Radiology 1968; 91: 1195-1198.
17. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A: Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 2005; 11: 1481-1493.
18. Heinemann A, Wischhusen F, Puschel K, Rogiers X: Standard liver volume in the Caucasian population. Liver Transpl Surg 1999; 5: 366-368.
19. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137: 675-680.
20. Ribero D, Chun YS, Vauthey JN: Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol 2008; 25: 104-109.
21. Truant S, Oberlin O, Sergent G, Lebuffe G, Gambiez L, Ernst O, Pruvot FR: Remnant liver volume to body weight ratio > or =0.5%: a new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg 2007; 204: 22-33.
22. Lo CM, Fan ST, Liu CL, Lo RJ, Lau GK, Wei WI, Li JH, Ng IO, Wong J: Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe graft. Transplantation 1997; 63: 1524-1528.
23. Marcos A, Fisher RA, Ham JM, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Fulcher AS, Posner MP: Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000; 69: 1375-1379.
24. Ito T, Kiuchi T, Yamamoto H, Oike F, Ogura Y, Fujimoto Y, Hirohashi K, Tanaka AK: Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. Transplantation 2003; 75: 1313-1317.
25. Lo CM, Fan ST, Chan JK, Wei W, Lo RJ, Lai CL: Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation 1996; 62: 696-698.
26. Chun YS, Ribero D, Abdalla EK, Madoff DC, Mortenson MM, Wei SH, Vauthey JN: Comparison of two methods of future liver remnant volume measurement. J Gastrointest Surg 2008; 12: 123-128.
27. Shindoh J, Truty MJ, Aloia TA, Curley SA, Zimmitti G, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN: Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liverrelated mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216: 201-209.
28. Hoekstra LT, de GW, Nibourg GA, Heger M, Bennink RJ, Stieger B, van Gulik TM: Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 2013; 257: 27-36.
29. van Gulik TM: Assessment of liver function: what are we measuring? HPB (Oxford) 2013; 15: 325-326.
30. Nagashima I, Takada T, Okinaga K, Nagawa H: A scoring system for the assessment of the risk of mortality after partial hepatectomy in patients with chronic liver dysfunction. J Hepatobiliary Pancreat Surg 2005; 12: 44-48.
31. Garcea G, Ong SL, Maddern GJ: Predicting liver failure following major hepatectomy. Dig Liver Dis 2009; 41: 798-806.
32. Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC: Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243: 373-379.
33. Kamath PS, Kim WR: The Model for End-Stage Liver Disease (MELD). Hepatology 2007; 45: 797-805.
34. Clavien PA, Emond J, Vauthey JN, Belghiti J, Chari RS, Strasberg SM: Protection of the liver during hepatic surgery. J Gastrointest Surg 2004; 8: 313-327.
35. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S: The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961; 21: 43-57.
36. de Graaf W, Hausler S, Heger M, van Ginhoven TM, van CG, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B: Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol 2011; 54: 738-745.
37. Paumgartner G: The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975; 105: 1-30.
38. Huang L, Vore M: Multidrug resistance p-glycoprotein 2 is essential for the biliary excretion of indocyanine green. Drug Metab Dispos 2001; 29: 634-637.
39. Hendrikse NH, Kuipers F, Meijer C, Havinga R, Bijleveld CM, van der Graaf WT, Vaalburg W, de Vries EG: In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother Pharmacol 2004; 54: 131-138.
40. Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J: Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997; 84: 1255-1259.
41. Fan ST, Lai EC, Lo CM, Ng IO, Wong J: Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995; 130: 198-203.
42. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J: Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004; 240: 698-708.
43. Torzilli G, Makuuchi M, Inoue K, Takayama T, Sakamoto Y, Sugawara Y, Kubota K, Zucchi A: No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg 1999; 134: 984-992.
44. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M: Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg 2005; 12: 16-22.
45. Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Takayama T, Makuuchi M: One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003; 138: 1198-1206.
46. Ohwada S, Kawate S, Hamada K, Yamada T, Sunose Y, Tsutsumi H, Tago K, Okabe T: Perioperative real-time monitoring of indocyanine green clearance by pulse spectrophotometry predicts remnant liver functional reserve in resection of hepatocellular carcinoma. Br J Surg 2006; 93: 339-346.
47. Suzuki Y, Kohno Y, Takeda Y, Hiraki Y: Evaluation of liver function parameters by Tc-99m-GSA using multivariate analysis: a study of 47 clinical cases. Acta Med Okayama 1999; 53: 225-232.
48. Sawamura T, Kawasato S, Shiozaki Y, Sameshima Y, Nakada H, Tashiro Y: Decrease of a hepatic binding protein specific for asialoglycoproteins with accumulation of serum asialoglycoproteins in galactosaminetreated rats. Gastroenterology 1981; 81: 527-533.
49. Kokudo N, Vera DR, Makuuchi M: Clinical application of TcGSA. Nucl Med Biol 2003; 30: 845-849.
50. Kwon AH, Ha-Kawa SK, Uetsuji S, Kamiyama Y, Tanaka Y: Use of technetium 99m diethylenetriamine-pentaacetic acid-galactosyl-human serum albumin liver scintigraphy in the evaluation of preoperative and postoperative hepatic functional reserve for hepatectomy. Surgery 1995; 117: 429-434.
51. Mimura T, Hamazaki K, Sakai H, Tanaka N, Mimura H: Evaluation of hepatic functional reserve in rats with obstructive jaundice by asyaloglycoprotein receptor. Hepatogastroenterology 2001; 48: 777-782.
52. Vera DR, Stadalnik RC, Trudeau WL, Scheibe PO, Krohn KA: Measurement of receptor concentration and forward-binding rate constant via radiopharmacokinetic modeling of technetium-99m-galactosyl-neoglycoalbumin. J Nucl Med 1991; 32: 1169-1176.
53. Miki K, Kubota K, Kokudo N, Inoue Y, Bandai Y, Makuuchi M: Asialoglycoprotein receptor and hepatic blood flow using technetium-99m-DTPA-galactosyl human serum albumin. J Nucl Med 1997; 38: 1798-1807.
54. Miki K, Kubota K, Inoue Y, Vera DR, Makuuchi M: Receptor measurements via Tc-GSA kinetic modeling are proportional to functional hepatocellular mass. J Nucl Med 2001; 42: 733-737.
55. Ha-Kawa SK, Tanaka Y: A quantitative model of technetium-99m-DTPA-galactosyl-HSA for the assessment of hepatic blood flow and hepatic binding receptor. J Nucl Med 1991; 32: 2233-2240.
56. Nanashima A, Yamaguchi H, Shibasaki S, Morino S, Ide N, Takeshita H, Sawai T, Nakagoe T, Nagayasu T, Ogawa Y: Relationship between indocyanine green test and technetium-99m galactosyl serum albumin scintigraphy in patients scheduled for hepatectomy: clinical evaluation and patient outcome. Hepatol Res 2004; 28: 184-190.
57. Kokudo N, Vera DR, Tada K, Koizumi M, Seki M, Matsubara T, Ohta H, Yamaguchi T, Takahashi T, Nakajima T, Muto T: Predictors of successful hepatic resection: prognostic usefulness of hepatic asialoglycoprotein receptor analysis. World J Surg 2002; 26: 1342-1347.
58. Kim YK, Nakano H, Yamaguchi M, Kumada K, Takeuchi S, Kitamura N, Takahashi H, Hasebe S, Midorikawa T, Sanada Y: Prediction of postoperative decompensated liver function by technetium-99m galactosyl-human serum albumin liver scintigraphy in patients with hepatocellular carcinoma complicating chronic liver disease. Br J Surg 1997; 84: 793-796.
59. Takeuchi S, Nakano H, Kim YK, Kumada K, Nagasaki H, Sasaki J, Sanada Y, Baek Y, Hasebe S, Midorikawa T, Yoshizawa Y, Yamaguchi M: Predicting survival and post-operative complications with Tc-GSA liver scintigraphy in hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 1855-1861.
60. Koizumi M, Yamada Y, Nomura E, Takiguchi T, Kokudo N: An easy and reproducible semiautomatic method for the evaluation of 99m Tc-galactosyl human serum albumin. Ann Nucl Med 1997; 11: 345-348.
61. Miki K, Matsui Y, Teruya M, Kaminishi M, Kokudo N: Index of convexity: a novel liver function index using Tc-GSA scintigraphy. World J Gastroenterol 2013; 19: 92-96.
62. Du S, Mao Y, Tong J, Li F, Che L, Li S, Yang H, Ba J, Hu N, Xing H, Lu X, Sang X, Zhang X, Wang X, Zhong S: A novel liver function evaluation system using radiopharmacokinetic modeling of technetium-99m-DTPAgalactosyl human serum albumin. Nucl Med Commun 2013; 34: 893-899.
63. Satoh K, Yamamoto Y, Nishiyama Y, Wakabayashi H, Ohkawa M: 99m Tc-GSA liver dynamic SPECT for the preoperative assessment of hepatectomy. Ann Nucl Med 2003; 17: 61-67.
64. Iimuro Y, Kashiwagi T, Yamanaka J, Hirano T, Saito S, Sugimoto T, Watanabe S, Kuroda N, Okada T, Asano Y, Uyama N, Fujimoto J: Preoperative estimation of asialoglycoprotein receptor expression in the remnant liver from CT/99mTc-GSA SPECT fusion images correlates well with postoperative liver function parameters. J Hepatobiliary Pancreat Sci 2010; 17: 673-681.
65. Beppu T, Hayashi H, Okabe H, Masuda T, Mima K, Otao R, Chikamoto A, Doi K, Ishiko T, Takamori H, Yoshida M, Shiraishi S, Yamashita Y, Baba H: Liver functional volumetry for portal vein embolization using a newly developed 99m Tc-galactosyl human serum albumin scintigraphy SPECT-computed tomography fusion system. J Gastroenterol 2011; 46: 938-943.
66. Hirai I, Kimura W, Fuse A, Suto K, Urayama M: Evaluation of preoperative portal embolization for safe hepatectomy, with special reference to assessment of nonembolized lobe function with 99m Tc-GSA SPECT scintigraphy. Surgery 2003; 133: 495-506.
67. Nishiyama Y, Yamamoto Y, Hino I, Satoh K, Wakabayashi H, Ohkawa M: 99m Tc galactosyl human serum albumin liver dynamic SPET for pre-operative assessment of hepatectomy in relation to percutaneous transhepatic portal embolization. Nucl Med Commun 2003; 24: 809-817.
68. Kwon AH, Matsui Y, Ha-Kawa SK, Kamiyama Y: Functional hepatic volume measured by technetium-99m-galactosyl-human serum albumin liver scintigraphy: comparison between hepatocyte volume and liver volume by computed tomography. Am J Gastroenterol 2001; 96: 541-546.
69. Kwon AH, Matsui Y, Kaibori M, Kamiyama Y: Functional hepatic regeneration following hepatectomy using galactosyl-human serum albumin liver scintigraphy. Transplant Proc 2004; 36: 2257-2260.
70. Tanaka A, Shinohara H, Hatano E, Sato S, Kanazawa A, Yamaoka Y, Torizuka T, Konishi J, Tamaki N: Perioperative changes in hepatic function as assessed by asialoglycoprotein receptor indices by technetium 99m galactosyl human serum albumin. Hepatogastroenterology 1999; 46: 369-375.
71. de Graaf W, Bennink RJ, Heger M, Maas A, de BK, van Gulik TM: Quantitative assessment of hepatic function during liver regeneration in a standardized rat model. J Nucl Med 2011; 52: 294-302.
72. Haubner R, Vera DR, Farshchi-Heydari S, Helbok A, Rangger C, Putzer D, Virgolini IJ: Development of 68 Ga-labelled DTPA galactosyl human serum albumin for liver function imaging. Eur J Nucl Med Mol Imaging 2013; 40: 1245-1255.
73. Loberg MD, Cooper M, Harvey E, Callery P, Faith W: Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. J Nucl Med 1976; 17: 633-638.
74. Krishnamurthy S, Krishnamurthy GT: Technetium-99m-iminodiacetic acid organic anions: review of biokinetics and clinical application in hepatology. Hepatology 1989; 9: 139-153.
75. Krishnamurthy GT, Krishnamurthy S: Cholescintigraphic measurement of liver function: how is it different from other methods? Eur J Nucl Med Mol Imaging 2006; 33: 1103-1106.
76. Ghibellini G, Leslie EM, Pollack GM, Brouwer KL: Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 2008; 25: 1851-1860.
77. Hendrikse NH, Kuipers F, Meijer C, Havinga R, Bijleveld CM, van der Graaf WT, Vaalburg W, de Vries EG: In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and Pglycoprotein. Cancer Chemother Pharmacol 2004; 54: 131-138.
78. Trauner M, Meier PJ, Boyer JL: Molecular pathogenesis of cholestasis. N Engl J Med 1998; 339: 1217-1227.
79. Heyman S: Hepatobiliary scintigraphy as a liver function test. J Nucl Med 1994; 35: 436-437.
80. Ekman M, Fjalling M, Friman S, Carlson S, Volkmann R: Liver uptake function measured by IODIDA clearance rate in liver transplant patients and healthy volunteers. Nucl Med Commun 1996; 17: 235-242.
81. Erdogan D, Heijnen BH, Bennink RJ, Kok M, Dinant S, Straatsburg IH, Gouma DJ, van Gulik TM: Preoperative assessment of liver function: a comparison of 99m Tc-mebrofenin scintigraphy with indocyanine green clearance test. Liver Int 2004; 24: 117-123.
82. Bennink RJ, Dinant S, Erdogan D, Heijnen BH, Straatsburg IH, van Vliet AK, van Gulik TM: Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. J Nucl Med 2004; 45: 965-971.
83. de Graaf W, Bennink RJ, Vetelainen R, van Gulik TM: Nuclear imaging techniques for the assessment of hepatic function in liver surgery and transplantation. J Nucl Med 2010; 51: 742-752.
84. de Graaf W, van Lienden KP, Dinant S, Roelofs JJ, Busch OR, Gouma DJ, Bennink RJ, van Gulik TM: Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J Gastrointest Surg 2010; 14: 369-378.
85. McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-1400.
86. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906.
87. Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, Rodes J, McGill DB, Reading CC, James EM, Charboneau JW, Ludwig J, Batts KP, Zinsmeister AR: The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079-1083.
88. de Graaf W, van Lienden KP, van Gulik TM, Bennink RJ: (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. J Nucl Med 2010; 51: 229-236.
89. George J, Murray M, Byth K, Farrell GC: Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21: 120-128.
90. Palmer CN, Coates PJ, Davies SE, Shephard EA, Phillips IR: Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of waxembedded archival material. Hepatology 1992; 16: 682-687.
91. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldana SN, Sorter M, Vinks AA, Nassr N, von RO, Jin L, Nebert DW: Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 2006; 16: 359-367.
92. Guengerich FP, Krauser JA, Johnson WW: Rate-limiting steps in oxidations catalyzed by rabbit cytochrome P450 1A2. Biochemistry 2004; 43: 10775-10788.
93. Schoeller DA, Schneider JF, Solomons NW, Watkins JB, Klein PD: Clinical diagnosis with the stable isotope 13 C in CO 2 breath tests: methodology and fundamental considerations. J Lab Clin Med 1977; 90: 412-421.
94. Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, Niehues SM, Schwabe M, Lemke AJ, Neuhaus P: Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009; 250: 119-125.
95. Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P: The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010; 12: 139-146.
96. Lock JF, Malinowski M, Seehofer D, Hoppe S, Rohl RI, Niehues SM, Neuhaus P, Stockmann M: Function and volume recovery after partial hepatectomy: influence of preoperative liver function, residual liver volume, and obesity. Langenbecks Arch Surg 2012; 397: 1297-1304.
97. McKinnon RA, Hall PD, Quattrochi LC, Tukey RH, McManus ME: Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 1991; 14: 848-856.
98. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L: Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging 2009; 29: 1323-1331.
99. Sourbron S, Sommer WH, Reiser MF, Zech CJ: Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Radiology 2012; 263: 874-883.
100. Saito K, Ledsam J, Sourbron S, Hashimoto T, Araki Y, Akata S, Tokuuye K: Measuring hepatic functional reserve using low temporal resolution Gd-EOB-DTPA dynamic contrast-enhanced MRI: a preliminary study comparing galactosyl human serum albumin scintigraphy with indocyanine green retention. Eur Radiol 2014; 24: 112-119.
101. Niekel MC, Bipat S, Stoker J: Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/ CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674-684.
102. Clement O, Muhler A, Vexler V, Berthezene Y, Brasch RC: Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol 1992; 27: 612-619.
103. Schuhmann-Giampieri G: Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol 1993; 28: 753-761.
104. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U: Preclinical evaluation of Gd-EOBDTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59-64.
105. Leonhardt M, Keiser M, Oswald S, Kuhn J, Jia J, Grube M, Kroemer HK, Siegmund W, Weitschies W: Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 2010; 38: 1024-1028.
106. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290: 153-157.
107. Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Schitt-Willich H: Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat. J Pharm Sci 1993; 82: 799-803.
108. Pascolo L, Petrovic S, Cupelli F, Bruschi CV, Anelli PL, Lorusso V, Visigalli M, Uggeri F, Tiribelli C: Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun 2001; 282: 60-66.
109. Schmitz SA, Muhler A, Wagner S, Wolf KJ: Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153 gadolinium-EOB-DTPA scintigraphy in rats. Invest Radiol 1996; 31: 154-160.
110. Kim T, Murakami T, Hasuike Y, Gotoh M, Kato N, Takahashi M, Miyazawa T, Narumi Y, Monden M, Nakamura H: Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging 1997; 7: 683-688.
111. Shimizu J, Dono K, Gotoh M, Hasuike Y, Kim T, Murakami T, Sakon M, Umeshita K, Nagano H, Nakamori S, Kato N, Miyazawa T, Nakamura H, Monden M: Evaluation of regional liver function by gadolinium-EOBDTPA-enhanced MR imaging. Dig Dis Sci 1999; 44: 1330-1337.
112. Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, Kim YS, Kang DS: Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol 2004; 5: 231-239.
113. Tsuda N, Okada M, Murakami T: Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007; 42: 242-247.
114. Tsuda N, Okada M, Murakami T: New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 2010; 73: 137-142.
115. Nilsson H, Blomqvist L, Douglas L, Nordell A, Janczewska I, Naslund E, Jonas E: Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol 2013; 86: 20120653.
116. Tschirch FT, Struwe A, Petrowsky H, Kakales I, Marincek B, Weishaupt D: Contrastenhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008; 18: 1577-1586.
117. Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T: Liver parenchymal enhancement of hepatocytephase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046.
118. Takao H, Akai H, Tajima T, Kiryu S, Watanabe Y, Imamura H, Akahane M, Yoshioka N, Kokudo N, Ohtomo K: MR imaging of the biliary tract with Gd-EOB-DTPA: effect of liver function on signal intensity. Eur J Radiol 2011; 77: 325-329.
119. Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, Shibahara J, Kokudo N, Akahane M, Ohtomo K: Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2010; 34: 362-366.
120. Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, Murakami T: Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 2011; 46: 277-283.
121. Nishie A, Ushijima Y, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Takayama Y, Okamoto D, Abe K, Obara M, Yoshimitsu K, Honda H: Quantitative analysis of liver function using superparamagnetic iron oxide-and Gd-EOB-DTPA-enhanced MRI: comparison with technetium-99m galactosyl serum albumin scintigraphy. Eur J Radiol 2012; 81: 1100-1104.
122. Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E: Assessment of liver function in primary biliary cirrhosis using Gd-EOBDTPA-enhanced liver MRI. HPB (Oxford) 2010; 12: 567-576.
123. Reeder SB, Cruite I, Hamilton G, Sirlin CB: Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011; 34: spcone.
124. van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, Ten Kate FJ, van Gulik TM, Stoker J: Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010; 256: 159-168.
125. Bohte AE, Garteiser P, De NA, Groot PF, Sinkus R, Stoker J, Nederveen AJ: MR elastography of the liver: defining thresholds for detecting viscoelastic changes. Radiology 2013; 269: 768-776.
126. Venkatesh SK, Yin M, Ehman RL: Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 2013; 37: 544-555.
127. Heger M, de Graaf W, Bennink RJ, Beuers U, van Gulik TM: A clinical perspective on the criteria for liver resection and the use of liver function tests. World J Surg 2010; 34: 868-869.
128. Bieze M, Klumpen HJ, Verheij J, Beuers U, Phoa SS, van Gulik TM, Bennink RJ: Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed tomography for intra-and extrahepatic hepatocellular carcinoma. Hepatology 2014; 59: 996-1006.